Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bacterial Flora of the Large Intestine01:29

Bacterial Flora of the Large Intestine

554
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
554
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

514
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
514
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

344
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
344
Anatomy of the Intestines01:23

Anatomy of the Intestines

72.8K
Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
72.8K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

384
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
384
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated Lipidomic and Amino Acid Metabolomic Analyses Reveal Muscle Metabolic Differences in Tibetan Sheep Under Grazing and House-Feeding Systems.

Animals : an open access journal from MDPI·2026
Same author

The perception of diabetes risk in minor children among parents with type 2 diabetes mellitus: a qualitative study.

Frontiers in public health·2026
Same author

Synbiotics and antioxidants synergistically attenuate disease progression in metabolic dysfunction-associated steatotic liver disease.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Integrating phenotypic and ceRNA network analyses reveals potential hypoxia adaptation mechanisms in Tibetan sheep skeletal muscles.

Genomics·2026
Same author

Differentiating Acute-onset Autoimmune Hepatitis From Drug-Induced Autoimmune-like Hepatitis: A Multicenter Study and Score Development.

Clinical reviews in allergy & immunology·2026
Same author

A circRNA-miRNA-mRNA network potentially regulates skeletal muscle adaptation to hypoxia in Tibetan sheep.

BMC genomics·2026

Related Experiment Video

Updated: Aug 9, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K

Intestinal microbiota in biliary diseases.

Qiyun Xia1, Qiaoyan Liu, Xiong Ma

  • 1Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai Institute of Digestive Disease, Shanghai, China.

Current Opinion in Gastroenterology
|February 23, 2023
PubMed
Summary

Gut microbiota alterations are implicated in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Research into these changes offers potential for new biomarkers and treatments for these liver diseases.

More Related Videos

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

11.3K
Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

9.5K

Related Experiment Videos

Last Updated: Aug 9, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K
Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

11.3K
Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

9.5K

Area of Science:

  • Hepatology
  • Microbiome Research
  • Immunology

Background:

  • Biliary diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), affect the bile tract and can lead to liver cirrhosis.
  • Limited therapeutic options exist for PBC and PSC, highlighting the need for novel treatment strategies.

Approach:

  • This review synthesizes recent evidence on the role of gut microbiota in the pathogenesis of PBC and PSC.
  • It examines alterations in gut microbiota composition observed in patients with these conditions.
  • The review discusses the potential mechanistic links between gut dysbiosis, immune activation, and liver injury.

Key Points:

  • Patients with PBC and PSC show distinct changes in their gut microbiota.
  • A compromised gut barrier may allow bacterial translocation and metabolite entry, contributing to autoimmune responses.
  • Molecular mimicry between bacterial and host antigens is a proposed mechanism for aberrant immune activation.

Conclusions:

  • The gut microbiota plays a significant role in the development and progression of PBC and PSC.
  • Understanding these microbial interactions opens avenues for developing innovative biomarkers.
  • Targeting the gut microbiota presents a promising therapeutic strategy for managing biliary diseases.